All Articles

As Indonesia Energy Corp drills its K-29 well, we explore the strategy behind the spin. Is this about barrels of oil or building investor confidence?

NervGen Pharma launches its pivotal Phase 3 RESTORE trial for spinal cord injury, backed by $61M in cash and new leadership, igniting hope for a new era of neuro-repair.

Q2 data reveals a stark divergence: private markets show steady, earnings-driven growth while public markets chase AI hype. But beneath the surface, a new era of selectivity emerges.

NeuPath Health's Q2 results show headline declines, but a deeper look reveals strong organic growth from record patient visits and strategic expansion.

Revenue is down, but Bragg Gaming's margins are up. A new chairman, a major acquisition, and deep cuts signal a high-stakes bet on a leaner future.

MSG Sports posts record profits fueled by a Knicks NBA title, but the real story is the strategic gamble to split its empire, creating long-term risks.

PO Wealth Sharing Group claims 200,000 users and a global footprint. But beneath the surface of this fintech success story lies a troubling pattern.

The FDA is betting on AI to manage chronic illness. Cadence's new pilot for its hypertension software could rewrite the rules for digital health regulation.

A new partnership between Flip Electronics and Vishay confronts the growing crisis of component obsolescence, promising a secure, authorized channel for legacy parts.

Facing a 'going concern' warning, Pulmatrix abandons its drug pipeline for a reverse merger, betting its survival on the high-risk field of longevity science.

ImpactFactory.ai launches a platform integrating 25+ AI engines to automate marketing, promising to democratize advertising. But what does this mean for the human creative?

Rigel's VEPPANU is the first FDA-approved PROTAC, a new class of drug that destroys disease proteins. This is the story behind the science and the numbers.

A Washington nonprofit reports a stunning 6% recidivism rate, far below national averages. We dissect the model combining aerospace manufacturing with social reform.

With a giant copper resource, Minsud Resources uses a clever partnership with South32 to fund a 10,500m drill program while preserving capital.

As CEO Gareth Sheridan takes the stage, his company's abuse-deterrent tech, AVERSA™, promises a new front in the opioid crisis. But can it deliver?

A startup's revolutionary 'space sling' just won a massive Space Force contract. Here's why this fuel-free platform could redefine orbital warfare.

Lurie Children's new facility is more than a pharmacy; it's a look into a new system where hospitals integrate business and care to survive and thrive.

Despite a sharp performance dip in July driven by an AI stock selloff, investors continue to pour capital into hedge funds for the seventh straight month.

Curis secures a crucial, albeit small, $5.6M funding lifeline. Will it be enough to push its promising cancer drug through trials before the clock runs out?

AM Best's top-tier rating affirms National Life Group's market strength, but a deeper look reveals a strategy balancing aggressive growth with complex challenges.